NCM
CUE icon

Nantahala Capital Management’s Cue Biopharma CUE Stock Holding History

Nantahala Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-890
Closed -$50.4K – 135
2024
Q1 		$50.4K Hold
890
– – ﹤0.01% 119
2023
Q4 		$70.5K Sell
890
-2
-0.2% -$143 ﹤0.01% 124
2023
Q3 		$61.5K Hold
892
– – 0.01% 128
2023
Q2 		$97.7K Sell
892
-2,218
-71% -$261K 0.01% 116
2023
Q1 		$333K Hold
3,110
– – 0.03% 111
2022
Q4 		$266K Hold
3,110
– – 0.02% 105
2022
Q3 		$208K Sell
3,110
-239
-7% -$20.6K 0.01% 106
2022
Q2 		$250K Sell
3,349
-71,463
-96% -$8.36M 0.01% 111
2022
Q1 		$11M Sell
74,812
-9,845
-12% -$2.09M 0.48% 40
2021
Q4 		$28.7M Sell
84,657
-1,046
-1% -$405K 1.01% 29
2021
Q3 		$37.5M Sell
85,703
-3,553
-4% -$1.24M 1.18% 25
2021
Q2 		$31.2M Sell
89,256
-877
-1% -$340K 0.89% 27
2021
Q1 		$33M Buy
90,133
+6,574
+8% +$2.71M 0.96% 28
2020
Q4 		$31.4M Buy
83,559
+5,485
+7% +$2.19M 0.97% 26
2020
Q3 		$35.3M Buy
78,074
+561
+0.7% +$323K 1.08% 19
2020
Q2 		$57M Sell
77,513
-5,948
-7% -$4.31M 1.72% 12
2020
Q1 		$35.5M Buy
83,461
+36,630
+78% +$17.8M 1.33% 19
2019
Q4 		$22.3M Buy
46,831
+891
+2% +$280K 0.69% 36
2019
Q3 		$11.6M Hold
45,940
– – 0.43% 47
2019
Q2 		$12.4M Buy
45,940
+16,670
+57% +$4.15M 0.38% 52
2019
Q1 		$6.79M Hold
29,270
– – 0.21% 64
2018
Q4 		$4.13M Buy
29,270
+833
+3% +$151K 0.13% 82
2018
Q3 		$7.72M Buy
28,437
+14,318
+101% +$4.14M 0.21% 63
2018
Q2 		$5.02M Buy
+14,119
New +$5.61M 0.2% 67

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Nantahala Capital Management's CUE Position: Q2 2024 in Review

Nantahala Capital Management sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 890 shares — an estimated $50.4K sold.

Nantahala Capital Management first reported a position in CUE in Q2 2018 and held it in 24 quarters. The position peaked at $57M in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Nantahala Capital Management reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 890 Cue Biopharma shares in Q2 2024, an estimated $50.4K.
  • Nantahala Capital Management first reported a position in Cue Biopharma in Q2 2018 and held it in 24 quarters.
  • Nantahala Capital Management's Cue Biopharma position peaked at $57M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Nantahala Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.